Lipid nanoparticles (LNPs) serve as core carriers for nucleic acid therapeutics, and their physicochemical properties largely depend on the precision of the manufacturing process. The assembly of LNPs is a complex physicochemical process, primarily involving the self-assembly of lipid components at the water/organic solvent interface. In both industrial and laboratory settings, the primary goal of manufacturing is to achieve rapid and uniform mixing of lipids with nucleic acids, producing nanoparticles with narrow size distribution, high encapsulation efficiency, and robust stability. The manufacturing process not only determines the initial quality of the particles but also directly impacts the difficulty of subsequent purification steps and the biological delivery efficiency of the therapeutics. Although multiple preparation methods exist, industry discussions mainly focus on precision mixing techniques represented by microfluidics and conventional mixing techniques exemplified by ethanol injection.
The table below summarizes the key evaluation parameters for LNP manufacturing, which serve as critical benchmarks for comparing different manufacturing approaches:
Table 1. Key Evaluation Parameters for LNP Manufacturing.
| Evaluation Dimension | Technical Definition and Importance | Target Value |
| Particle Size | Average diameter of particles, affecting in vivo distribution and cellular uptake | Typically 60–100 nm |
| Polydispersity Index (PDI) | Measures the uniformity of particle size distribution | Ideal < 0.2, lower values indicate more uniform distribution |
| Encapsulation Efficiency (EE%) | Fraction of nucleic acid encapsulated within particles relative to total input | Typically > 80% |
| Mixing Efficiency | Rate at which the two-phase fluids achieve molecular-level mixing | Mixing time should be shorter than the lipid self-assembly time |
| Throughput | Volume of material processed per unit time | Depends on R&D or production stage requirements |
Microfluidics is an advanced manufacturing approach that manipulates fluids at the micrometer scale. Its core principle is to use specially designed microchannels to collide and mix an ethanol phase containing lipids with an aqueous phase containing nucleic acids with extremely high precision.
Physical Mechanism: Controlled molecular diffusion. Within micrometer-scale channels, fluid flow typically operates at low Reynolds numbers, exhibiting laminar flow characteristics. Microfluidics leverages channel designs, such as cross-flow or staggered herringbone mixers, to increase the contact area between phases, allowing solvent exchange to occur through controlled molecular diffusion within milliseconds. This highly predictable kinetic environment ensures that LNP formation is highly reproducible.
Process Advantages:
Highly tunable particle size: Adjusting the flow rate ratio (FRR) and total flow rate (TFR) allows precise control of particle size without changing buffer composition.
Excellent uniformity: Extremely short mixing times ensure that all lipid molecules experience nearly identical supersaturation conditions, producing very narrow PDI distributions.
Easy laboratory optimization: Handling volumes as low as microliters makes microfluidics ideal for early-stage screening of expensive lipids or nucleic acid sequences.
Technical Challenges: While microfluidics provides significant advantages in precise control, large-scale production remains challenging. The throughput of a single-channel chip is limited, and industrial solutions often rely on parallelization of multiple microchannels to overcome this limitation.
Ethanol injection is a classical LNP preparation technique with a long history and relatively low equipment requirements. In this method, an organic solvent (typically ethanol) containing dissolved lipid components is rapidly injected into an aqueous buffer containing nucleic acids.
Physical Mechanism: Macroscale turbulent mixing. Ethanol injection relies primarily on turbulence generated by injection momentum or vigorous mechanical stirring to achieve mixing of the two phases. Upon entering the aqueous environment, the change in solvent polarity causes a sudden decrease in lipid solubility, triggering self-assembly. Unlike microfluidics, this mixing occurs in a large-volume space, and the mixing rate is influenced by syringe flow rate, needle diameter, and shear forces from stirring.
Process Features:
Simple equipment architecture: Requires only a high-precision syringe pump and a stirred reaction vessel, without complex microfabricated chips.
High throughput potential: Capable of rapidly processing large volumes for coarse-scale production.
Lower maintenance requirements: Hardware is less prone to clogging compared to microfluidic chips.
Limitations: Ethanol injection offers less precise control. Maintaining synchronous mixing throughout the vessel is challenging, which can result in local concentration gradients and broader particle size distributions. The method also heavily depends on operator skill, which may affect reproducibility across labs or batches.
Table 2. Comparison of Microfluidics and Ethanol Injection Techniques.
| Feature | Microfluidics | Ethanol Injection |
| Mixing Principle | Controlled laminar flow and molecular diffusion | Turbulent diffusion and mechanical shear |
| Particle Size Distribution (PDI) | Very narrow, typically < 0.1 | Wider, typically > 0.15 |
| Batch-to-Batch Consistency | Very high, highly programmable | Moderate, affected by operator variability |
| Production Scale | Scalable by increasing the number of channels | Scalable by increasing reactor volume |
| Initial Sample Loss | Very low, suitable for precious materials | Higher, due to dead volume in the system |
In LNP manufacturing, key process parameters directly influence particle size, uniformity, encapsulation efficiency, and batch-to-batch consistency. Microfluidics and ethanol injection differ significantly in operational principles and parameter control. In both microfluidics and ethanol injection, fluid flow rates and mixing efficiency are critical factors affecting particle formation and size distribution. Microfluidics relies on precisely controlled flow rate ratios and total flow rates to achieve rapid, uniform molecular-level mixing, while ethanol injection primarily depends on injection momentum and mechanical stirring, making mixing more sensitive to operator handling.
Table 3. Comparison of Flow Rate, Mixing Efficiency, and Particle Size Control.
| Comparison Dimension | Microfluidics | Ethanol Injection |
| Key Parameters | FRR and TFR | Solvent volume ratio and injection speed |
| Mixing Mechanism | Laminar flow + molecular diffusion, highly controlled | Turbulent flow + mechanical shear, sensitive to operator handling |
| Particle Size Control | Precisely adjustable via FRR/TFR, typically 20–150 nm | Adjusted by solvent ratio and injection speed, typically 50–200 nm |
| Polydispersity Index (PDI) | Very narrow, usually < 0.1 | Wider, usually 0.15–0.3 |
| Batch-to-Batch Consistency | Highly reproducible, software-controlled | Moderate, affected by operator variability and local mixing differences |
Solvent ratios, injection speed, and operational stability are another core dimension for comparing LNP manufacturing. These parameters directly affect particle formation efficiency, batch consistency, and scalability. Microfluidics achieves precise control of fluid proportions and flow rates through microchannels, while ethanol injection relies on injection speed and stirring intensity, making it more sensitive to human factors.
Table 4. Comparison of Solvent Ratios, Injection Speed, and Batch Consistency.
| Comparison Dimension | Microfluidics | Ethanol Injection |
| Solvent Control | Ethanol and aqueous phases precisely mixed through microchannels | Lipid-ethanol solution rapidly injected into aqueous phase, with potential local concentration gradients |
| Injection / Flow Rate | Precisely controlled, mixing completed within milliseconds | Injection speed depends on pump rate and needle size, mixing efficiency can fluctuate |
| Batch Consistency | Very high, software-controlled for reproducibility | Moderate, operator variability can affect batch-to-batch consistency |
| Scalability | Can be scaled by parallelizing multiple channels | Can be scaled by increasing reactor volume, but precision is limited |
| Sample Loss | Very low, suitable for precious materials | Relatively higher, with dead volume in the system |
Fig.1 LNP particle size distribution: Microfluidics vs. Ethanol Injection (BOC Sciences Original).
Microfluidics, a benchmark in nanomedicine manufacturing, achieves precise fluid control through extreme spatial confinement. This precision advances LNP production but comes with technical thresholds.
High particle uniformity: Mixing occurs on microsecond timescales in a controlled environment, producing LNPs with very narrow PDI and reduced batch variability.
High encapsulation efficiency: Optimal lipid-nucleic acid arrangement allows >90% nucleic acid encapsulation.
Low material consumption: Minimal dead volume enables process development with only microliters of material, reducing R&D costs.
Linear scale-up: Parallelization of mixing units avoids hydrodynamic distortion and shortens the lab-to-production timeline.
High equipment cost: Requires precision pumps and microfabricated chips, with substantial initial investment.
Risk of chip clogging: Lipid precipitation or microbubbles can block channels, requiring high raw material purity and close monitoring.
Throughput limitations: Single-channel capacity is limited; parallelization helps but may still be insufficient for large-scale production.
Ethanol injection is a traditional LNP method, valued for simplicity and large-volume processing. It is less precise but effective in specific applications.
High production throughput: Suitable for large batches; scaling with larger vessels or high-flow pumps allows processing liters to hundreds of liters quickly.
Simple equipment: Uses standard chemical synthesis setups, enabling fast facility setup and easy maintenance/CIP.
Low technical barrier: Operation is intuitive, allowing technicians to quickly master the process.
Particle size control: Turbulent mixing causes broader size distributions, often requiring extrusion to achieve uniformity.
Batch consistency challenges: Minor differences in injection speed, stirring, or vessel shape can affect product properties, reducing reproducibility.
Raw material utilization variability: Local concentration gradients in large volumes lead to fluctuating encapsulation efficiency.
As a technology partner dedicated to nanomedicine translation, we understand that the choice of LNP manufacturing strategy directly impacts your project's R&D timeline, product quality, and ultimate commercial competitiveness. Selecting an LNP preparation method is not merely a matter of comparing technical performance; it requires a customized assessment based on the project stage, cost expectations, and delivery objectives. Based on our extensive process expertise, we provide the following guidance tailored to clients at different development stages:
If your project is in the early screening, formulation optimization, or personalized cancer vaccine development stage, we strongly recommend Microfluidics.
Service Value: At this stage, nucleic acid materials are highly valuable. Microfluidics minimizes dead volume, allowing you to produce high-quality LNPs with extremely narrow PDI with minimal material input. Highly digitalized parameter control ensures your experimental data is robust and persuasive for subsequent regulatory submissions.
Applicable Scenarios: Cationic lipid screening; siRNA/mRNA delivery efficiency evaluation; Rare ligand modification studies.
For infectious disease vaccines, public health products, or biosimilar projects sensitive to cost, Ethanol Injection remains a highly cost-effective industrial choice.
Service Value: When your goal is rapid supply of millions of doses, ethanol injection offers unmatched advantages in scale-up speed and fixed asset ROI. We assist in optimizing macro-scale mixing and shear conditions to minimize quality gaps relative to precision methods.
Applicable Scenarios: Influenza vaccines; Large-scale preventive immunizations; Capacity expansion for established product pipelines.
For clients preparing for pilot-scale production or Phase I/II clinical studies, we recommend evaluating "development convenience" versus "production scalability."
Service Value: We provide end-to-end support from microfluidic prototype preparation to multi-channel parallel scale-up. If your product is planned for technology transfer across multiple global sites, the digital replication capability of microfluidics can save significant cross-site debugging time.
Applicable Scenarios: IND-enabling studies for clinical submission; CDMO contract projects.
Table 5. LNP Manufacturing Process Selection Service Matrix.
| Client Priority | Recommended Method | Supplier Expert Perspective |
| Material Saving | Microfluidics | Minimizes sample loss, ideal for expensive mRNA/lipid R&D |
| Size Precision | Microfluidics | Achieves PDI < 0.1, meeting stringent targeting requirements |
| Rapid Scale-up | Ethanol Injection | Leverages large-volume reactors to quickly increase batch output |
| ROI on Equipment | Ethanol Injection | Uses widely available hardware, lowering per-dose production cost |
| Batch Consistency | Microfluidics | Automated, program-driven control eliminates human error |
As a professional service provider in drug delivery technologies, we offer not only advanced hardware support but also end-to-end solutions spanning from laboratory development to commercial translation. Whether you choose the precision path of microfluidics or the large-scale production path of ethanol injection, our expert team ensures your process achieves industry-leading stability, reproducibility, and product performance. Below are the core technical support services we provide:
The core of microfluidic process development lies in identifying the "optimal window" between fluid dynamics and biochemical formulation. Through highly digitalized methods, we help clients maximize the precision advantages of microfluidics.
FRR and TFR Screening: Using automated platforms, we quickly establish correlations between process parameters and LNP size and PDI, helping clients lock in optimal production parameters in minimal time.
Mixer Structure Customization: For lipid formulations with unique viscosities, we evaluate the adaptability of various microchannel structures, such as staggered herringbone (SHM) and cross-flow designs, to optimize mixing efficiency and prevent channel clogging.
Formulation Sensitivity Analysis: We assess how the micro-laminar environment affects EE% under different nucleic acid loadings (N/P ratios), ensuring maximal utilization of valuable materials.
To address control limitations in traditional ethanol injection, we provide engineering improvements aimed at enhancing production predictability and consistency.
Precision Injection System Integration: By introducing high-precision constant-pressure pumps and automated feedback control systems, we replace manual operations and maintain consistent instantaneous energy as the organic phase enters the aqueous phase, significantly narrowing particle size distribution.
Macro-Scale Mixing Optimization: Using computational fluid dynamics (CFD) simulations, we optimize stirrer design and injection point locations within the reactor to eliminate dead zones and reduce particle aggregation caused by local concentration gradients.
Solvent Residue Control: In combination with ethanol injection, we develop high-efficiency tangential flow filtration (TFF) concentration and elution processes to ensure final product ethanol levels remain far below regulatory thresholds.
Table 6. LNP Manufacturing and Characterization Services.
Scaling from "microliters" to "hundreds of liters" is a critical bottleneck in LNP drug commercialization. Using scientific scale-up logic, we ensure your process achieves "lossless translation" across different production scales.
Microfluidics Parallelization (Numbering-up): We assist clients in transferring lab-optimized chip parameters to multi-channel production platforms, multiplying output without re-optimizing process parameters.
Cross-Platform Tech Transfer: We provide comprehensive SOP development to ensure the process is highly reproducible across sites and batches, reducing validation costs.
Process Economics Assessment: For large-scale production, we evaluate yield, consumable usage, and time costs across different production line configurations, providing optimized equipment depreciation and ROI recommendations.
References
